Fig. 5: Lung tissue distribution of nebulized PRS-220 in ex vivo ventilated and perfused human lungs. | Nature Communications

Fig. 5: Lung tissue distribution of nebulized PRS-220 in ex vivo ventilated and perfused human lungs.

From: Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment

Fig. 5

a Scheme of the ex vivo lung perfusion (EVLP) set-up with the nebulizer set-up in line with the ventilation tubing. Created in BioRender. Pavlidou, M. (2025) https://BioRender.com/f59h729b Picture of the actual EVLP experiment. c Overview immunofluorescence imaging of EVLP lung biopsies 4 h after nebulized delivery of Alexa Fluor 647-labeld PRS-220 (magenta). Cell nuclei (stained with DAPI (blue) and scale bar 1 mm). d Co-staining of lung tissue sections for CCN2 (red), smooth muscle actin (SMA, green) and DAPI (blue) at baseline (0 h, serving as negative control) and 2 and 4 h after nebulized delivery of Alexa Fluor 647-labeld PRS-220 (magenta). Biopsies from two different regions of the lung were analyzed at the terminal 4 h timepoint (Biopsy A and B). Figure shows images at 2 different magnifications (scale bars 500 µm for upper images and 100 µm for images below). e Co-immunofluorescence imaging of PRS-220 (magenta), CCN2 (red), platelet-derived growth factor α (PDGFRα, green) and DAPI (blue). f Co-immunofluorescence imaging of PRS-220 (magenta), CCN2 (red), keratin-5 (KRT5, green) and DAPI (blue). Figure shows representative images from independent experiments performed with n = 3 human donor lungs.

Back to article page